ライフサイエンスコーパス: blood disorder

1 Myelofibrosis (MF) is a devastating blood disorder.

2 a mechanosensitive ion channel involved in a blood disorder.

3 r mutations are responsible for a variety of blood disorders.

4 at is used to treat preleukemic and leukemic blood disorders.

5 tributed between malignant and non-malignant blood disorders.

6 mpanion Article to obtain the total costs of blood disorders.

7 from individuals without evidence of clonal blood disorders.

8 ce and for therapeutic strategies in genetic blood disorders.

9 ietic grafts to treat inherited and acquired blood disorders.

10 lymphocytic leukemia (CLL) and other clonal blood disorders.

11 y atherosclerosis, but also septic emboli or blood disorders.

12 velopment and provide new insight into human blood disorders.

13 spectrin tetramer formation, and may lead to blood disorders.

14 o the pathophysiology of cardiopulmonary and blood disorders.

15 ation in cellular immunotherapy of malignant blood disorders.

16 o generate transplantable cells for treating blood disorders.

17 apeutic potential of RNAi for treating these blood disorders.

18 mportant target for the treatment of various blood disorders.

19 ed levels of engraftment for gene therapy of blood disorders.

20 In one form of beta-thalassemia, a genetic blood disorder, a mutation in intron 2 of the beta-globi

21 d to assess the economic burden of malignant blood disorders across the 28 countries in the European

22 assess the economic burden of non-malignant blood disorders across the 28 countries of the European

23 f myeloid-biased HSCs, with implications for blood disorders, aging, and immunity.

24 m underlying a variant form of the inherited blood disorder alpha thalassemia.

25 globin gene transfer in treating a fulminant blood disorder and strongly support the efficacy of gene

26 upregulated in a variety of human neoplastic blood disorders and constitutive upregulation of miR-125

27 esis, and cell transplantation as related to blood disorders and hematopoietic development.

28 udied exclusively in patients with inherited blood disorders and hepatitis C virus (HCV) infection.

29 e as a treatment modality to rectify genetic blood disorders and improve cellular therapies.

30 ity to infectious diseases, atherosclerosis, blood disorders and neurosensory disorders.

31 SCD is a frequently inherited blood disorder, and sickle cell anemia is a common type

32 effective treatment for leukemia, lymphoma, blood disorders, and autoimmune diseases.

33 nge of diseases including anaemia, malignant blood disorders, and haemorrhagic disorders.

34 Malignant blood disorders are a leading contributor to cancer inci

35 Congenital blood disorders are common and yet clinically challengin

36 -globin, which are manifest in the inherited blood disorder beta thalassemia.

37 The blood disorder, beta-thalassaemia, is considered an attr

38 poietic cells from unrelated donors can cure blood disorders but carries a significant risk of acute

39 s, including acute leukaemias and congenital blood disorders, but obtaining suitable numbers of cells

40 genital, disease-associated, or drug-induced blood disorders can cause significant morbidities and mo

41 Beta-thalassemia is a severe genetic blood disorder caused by a mutation in the gene encoding

42 a (beta-Thal) is a group of life-threatening blood disorders caused by either point mutations or dele

43 beta-thalassemia (betaT) is a genetic blood disorder causing profound and life threatening ane

44 Sickle cell disease is an inherited blood disorder characterized by chronic hemolytic anemia

45 ickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic anemia, episod

46 CSAs) are a heterogeneous group of inherited blood disorders characterized by pathological mitochondr

47 Patients with blood disorders colonized with antibiotic-resistant bact

48 Blood disorders comprise a wide range of diseases includ

49 costs in the EU (euro143 billion), malignant blood disorders cost euro12 billion (8%).

50 For the EU countries, malignant blood disorders cost euro6.8 billion (12%) of the total

51 Malignant blood disorders cost the 31 European countries euro12 bi

52 Our study also shows that blood disorder costs were evenly distributed between mal

53 c cell transplant (HCT) for the treatment of blood disorders, even with optimal donor HLA matching an

54 these costs we added those due to malignant blood disorders (ICD-10 C81-96 and D47) as estimated in

55 ll disease (SCD) is a highly complex genetic blood disorder in which red blood cells (RBC) exhibit he

56 assess the economic effect of non-malignant blood disorders in Europe.

57 enzene is an industrial chemical that causes blood disorders, including acute myeloid leukemia.

58 ion of metabolism in HSCs results in various blood disorders, including leukemia.

59 the pathophysiology and treatment of several blood disorders, including the anaemia of renal disease.

60 FMT in patients with blood disorders is safe and promotes eradication of ARB

61 ain impediments to effective gene therapy of blood disorders is the resistance of human hematopoietic

62 Sickle cell anemia is a blood disorder, known to affect the microcirculation and

63 obesity, infectious disease susceptibility, blood disorders, neurosensory disorders, drug addiction

64 icity testing and treatment of patients with blood disorders or malignancies.

65 ights the economic burden that non-malignant blood disorders place on European health-care systems an

66 Non-malignant blood disorder-related costs (WHO International Classifi

67 Malignant blood disorder-related costs were estimated for 28 EU co

68 Malignant blood disorders represent a leading cause of death, heal

69 ovide a new candidate for the rare inherited blood disorder stomatocytosis with uncompensated anemia.

70 g of the erythrocyte mechanics in hereditary blood disorders such as spherocytosis, elliptocytosis, a

71 a-globin mRNA and protein and to the genetic blood disorder thalassemia.

72 Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occ

73 turnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bon

74 Combining malignant and non-malignant blood disorders, the total cost of blood disorders was e

75 The "royal disease," a blood disorder transmitted from Queen Victoria to Europe

76 utations in these genes are commonly seen in blood disorders underscores their critical roles and hig

77 malignant blood disorders, the total cost of blood disorders was euro23 billion in 2012.

78 For countries in the EU, malignant blood disorders were compared with the economic burden o

79 ifying disease-causing variants in Mendelian blood disorders were identified and implemented as AbFab

80 t patients had primary immunodeficiencies or blood disorders, while 4 others had abnormal immune func

81 ll disease (SCD) is a debilitating monogenic blood disorder with a highly variable phenotype characte